Is Aristo Bio-Tech overvalued or undervalued?

As of 17 June 2025, the valuation grade for Aristo Bio-Tech has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued based on its key ratios, including a PE ratio of 19.37, an EV to EBITDA of 10.67, and a PEG ratio of 4.72. These figures suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Aristo Bio-Tech's valuation stands out as notably high, especially when juxtaposed with P I Industries, which has a PE ratio of 38.11, and Bayer CropScience, with a PE ratio of 44.78. This disparity highlights that Aristo Bio-Tech is not only overvalued relative to its industry but also underperforming in terms of stock returns, having declined by 13.16% year-to-date compared to a 5.11% increase in the Sensex. Overall, the analysis concludes that Aristo Bio-Tech is overvalued in the current market environment.